Roberto Bellini, CEO, Director and 10% Holder, acquired 1,315,789 Common Shares on a direct ownership basis at a price of $0.380 through a prospectus or prospectus exempt offering on December 12th, 2017. This represents a $500,000 investment into the company's shares and an account share holdings change of greater than 100%.
BELLUS Health is in the Pharmaceuticals Sub Industry Group under the Healthcare Sector.
BELLUS Health Inc is a Canada-based biopharmaceutical development company. The Company's pipeline of projects includes the BLU-5937 for chronic cough and several other partnered clinical-stage drug development programs. BLU-5937 is a potent, selective, orally bio-available small molecule antagonist of the P2X3 receptor, a clinically validated target for chronic cough. BLU-5937 has the potential to help a number of chronic cough patients who do not respond to current therapies. BELLUS Health Inc also has economic interests in other partnered clinical-stage drug development programs, including KIACTA for sarcoidosis, AMO-01 for Fragile X Syndrome and ALZ-801 for APOE4 homozygous Alzheimer's disease. BELLUS Health Inc. (BLU) has a high amount of executive buying compared to its micro-cap peers in the market over the past three months. According to regulatory filings yesterday, one insider has invested a total amount of $500,000.
No Comments